Cryptogenic Cirrhosis and Sitosterolemia: A Treatable Disease If Identified but Fatal If Missed

Fateh Bazerbachi1, Erin E Conboy2, Taofic Mounajjed3

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

Annals of Hepatology
|October 23, 2017
PubMed

Insights

Sitosterolemia, a rare metabolic disorder, can cause severe liver disease like cirrhosis, challenging previous understanding. Early diagnosis and hepatology evaluation are crucial for managing this under-recognized condition.

Area of Science:

  • Biochemistry
  • Genetics
  • Hepatology

Background:

  • Sitosterolemia is an autosomal recessive metabolic disorder.
  • It results from mutations in ABCG5 or ABCG8 genes, affecting xenosterol transport.
  • Liver involvement is considered rare, with only one prior report of cirrhosis.

Observation:

  • A fatal case of a 21-year-old South Asian male with decompensated cirrhosis and biochemical signs of sitosterolemia is presented.
  • Genetic analysis confirmed a homozygous pathogenic mutation in the ABCG5 gene.
  • This case highlights a potential link between sitosterolemia and severe liver disease.

Findings:

  • Sitosterolemia can manifest with severe hepatic involvement, including cirrhosis.
  • The condition is likely under-recognized in patients with cryptogenic cirrhosis.
  • Genetic confirmation of ABCG5/ABCG8 mutations is key for diagnosis.

Implications:

  • Sitosterolemia should be considered in the differential diagnosis of unexplained cirrhosis.
  • Prompt diagnosis allows for effective oral therapies.
  • Patients require thorough hepatology evaluation for liver disease monitoring.

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
27
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
223
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
404